Clinical Trial: Rituximab in Eosinophilic Granulomatosis With Polyangiitis

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional



Official Title: Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis.

Brief Summary:

Phase III, comparative, multicenter, randomized, controlled, double-blind and superiority research, comparing rituximab-based regimen with conventional therapeutic strategy for the induction of remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Patients with newly diagnosed or relapsing EGPA will be randomized in a 1:1 ratio to receive:

  • Experimental therapeutic strategy based on the use of rituximab (experimental group)
  • Conventional therapeutic strategy based on Five-Factor Score (FFS)-assessed disease severity (comparative group)